Alloimmunization, Sickle Cell Disease
Conditions
Brief summary
The focus of the study is the pathophysiological mechanism of allo-antibody formation after red blood cell transfusion in sickle cell disease patients.
Detailed description
The main objectives of this study are to study the role of the innate and adaptive immune response in allo-antibody formation and furthermore to identify the genetic and time dependent clinical risk factors on alloimmunization in SCD patients. Subjects without allo-antibodies, receiving a red blood cell transfusion, will be included in this study. At 5 time points blood will be drawn from these subjects. (T0: Before transfusion, T1: 1 day after transfusion, T2: 1 week after transfusion, T3: 4 weeks after transfusion, T4: 6 months after transfusion). At each time point specific markers of the immune system will be measured.
Interventions
None listed
Sponsors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Radboud University Medical Center
HagaZiekenhuis
Erasmus Medical Center
Sanquin Research & Blood Bank Divisions
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Sickle cell disease * Receiving a red blood cell transfusion
Exclusion criteria
* Previous positive screen for allo-antibodies * \>25 red blood cell units in the past
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The innate and adaptive immune response of patients with sickle cell disease that form allo-antibodies following erythrocyte transfusion, compared to patients that do not form alloantibodies following erythrocyte transfusion | 6 months | Multiple activating and regulatory markers of the innate and adaptive immune system will be measured at the indicated time points and compared between cases and controls |
Countries
Netherlands
Contacts
Primary ContactKarin Fijnvandraat, MD PhD
Outcome results
None listed